Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy
Journal of Controlled Release · 2023-09 · 361 · 270-279
DOI: 10.1016/j.jconrel.2023.07.062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-09. Verfasst von Jing Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West W…. Hauptthemen laut MEDLINE: Prodrugs, Heterocyclic Compounds, Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Zhejiang University.
Abstract (Originalsprache)
Proteolysis-targeting chimera (PROTAC) is emerging as a new strategy to degrade target proteins in a precise way by taking advantage of the cellular ubiquitin-proteasome system. However, the potential cytotoxicity of PROTAC should be avoided to mitigate the off-target degradation of proteins in healthy tissues or cells. To address this issue, we herein present a strategy to cage a PROTAC with 4-(vinyloxy) benzyl carbonate (MZ1-O), which can be eliminated through a 3,6-dimethyl-1,2,4,5-tetrazine (Tz)-mediated inverse electron-demand Diels-Alder (iEDDA) reaction to generate a BRD4 (bromodomain-containing protein 4) degrader, MZ1. We further propose a dissolvable microneedle-assisted strategy for site-specific activation of MZ1-O that is delivered by a targeted delivery vector through systemic route in vivo, and demonstrate such a bioorthogonal strategy is efficient and precise for tumor treatment. Our study suggests that the bioorthogonal activation of PROTAC-based prodrug offers a highly specific and precise approach for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou 311121, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, H…
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: bowen_li@zju.edu.cn.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou 311121, China. Electronic address: pingy@zju.edu.c…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Zhejiang University
- National Key Research and Development Program of China
- Science Fund for Distinguished Young Scholars of Zhejiang Province
Zitieren
APA
Huang, J., Yao, Z., Li, B., & Ping, Y. (2023). Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy. Journal of Controlled Release, 361, 270-279. https://doi.org/10.1016/j.jconrel.2023.07.062
Vancouver
Huang J, Yao Z, Li B, Ping Y. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy. Journal of Controlled Release. 2023;361:270-279. doi:10.1016/j.jconrel.2023.07.062
BibTeX
@article{Huang2023,
author = {Huang, Jing and Yao, Zhuo and Li, Bowen and Ping, Yuan},
title = {Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy},
journal = {Journal of Controlled Release},
year = {2023},
volume = {361},
pages = {270--279},
doi = {10.1016/j.jconrel.2023.07.062}
}
EUVIMED